Back to Journals » Infection and Drug Resistance » Volume 11

Peptide dendrimers as “lead compounds” for the treatment of chronic lung infections by Pseudomonas aeruginosa in cystic fibrosis patients: in vitro and in vivo studies

Authors Pompilio A, Geminiani C, Mantini P, Siriwardena TN, Di Bonaventura I, Reymond JL, Di Bonaventura G

Received 22 March 2018

Accepted for publication 4 May 2018

Published 11 October 2018 Volume 2018:11 Pages 1767—1782

DOI https://doi.org/10.2147/IDR.S168868

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 2

Editor who approved publication: Dr Joachim Wink


Arianna Pompilio,1,2 Cristina Geminiani,1,2 Paolo Mantini,1,2 Thissa N Siriwardena,3 Ivan Di Bonaventura,3 Jean Louis Reymond,3 Giovanni Di Bonaventura1,2

1Department of Medical, Oral, and Biotechnological Sciences, G d’Annunzio University of Chieti-Pescara, Chieti 66100, Italy; 2Center of Excellence on Aging and Translational Medicine, G d’Annunzio University of Chieti-Pescara, Chieti, Italy; 3Department of Chemistry and Biochemistry, University of Bern, Bern, Switzerland

Aim: In the present work, the potential of the D-enantiomeric dendrimers dG3KL and dTNS18 was evaluated in relation to tobramycin (Tob), for the development of novel antibacterials to treat Pseudomonas aeruginosa chronic lung infections in patients with cystic fibrosis.
Results: The activity of dendrimers against planktonic P. aeruginosa cells was less than Tob against three of the four strains tested (median minimum inhibitory concentration [MIC] 8 vs 1 µg/mL, respectively), but 32-fold higher against the PaPh32 strain isolated at posttransplantation stage. Results from comparative minimum bactericidal concentration/MIC evaluation and time–kill assay suggested a bactericidal mechanism for all test agents. Subinhibitory concentrations of both dendrimers and Tob significantly affected biofilm formation by all strains in a dose-dependent manner, although the PaPh26 strain, isolated during the chronic stage of infection, was particularly susceptible to dendrimers. The activity of dendrimers against preformed P. aeruginosa biofilm was generally comparable to Tob, considering both dispersion and viability of biofilm. Particularly, exposure to the test agent at 10 × MIC caused significant biofilm death (>90%, even to eradication), though with strain-specific differences. Single administration of dendrimers or Tob at 10 × MIC was not toxic in Galleria mellonella wax-moth larvae over 96 hours. However, contrarily to Tob, dendrimers were not protective against systemic infection caused by P. aeruginosa in G. mellonella. Kinetics of P. aeruginosa growth in hemolymph showed that bacterial load increased over time in the presence of dendrimers.
Conclusion: Overall, our findings indicated that dG3KL and dTNS18 peptide dendrimers show in vitro activity comparable to Tob against both P. aeruginosa planktonic and biofilm cells at concentrations not toxic in vivo. Further studies are warranted to explore different dosages and to increase the bioavailability of the peptides to solve the lack of protective effect observed in G. mellonella larvae.

Keywords: cystic fibrosis, chronic infection, Pseudomonas aeruginosa, dendrimer peptides, biofilm

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]